Belantamab Mafodotin provides a BCMA-targeting antibody-drug conjugate (ADC) for multiple myeloma and oncology research and specifically combines a B-cell maturation antigen (BCMA)-directed monoclonal antibody with monomethyl auristatin F (MMAF), supporting studies of targeted cytotoxicity, plasma cell malignancies, and ADC mechanisms.
Key Features and Benefits
- BCMA-Targeting ADC: Combines a BCMA-directed monoclonal antibody with the cytotoxic MMAF payload specifically for targeted cancer research.
- MMAF Payload: Contains monomethyl auristatin F, a potent microtubule-disrupting agent used in ADC research.
- BCMA Recognition: Supports investigation of BCMA expression, antibody binding, internalization, and plasma cell targeting.
- Non-Cleavable Linker: Uses a stable maleimidocaproyl (mc) linker that specifically supports intracellular processing and release of active MMAF-containing catabolites.
- Targeted Payload Delivery: Supports investigation of antibody-mediated delivery of MMAF to BCMA-expressing myeloma cells.
- Microtubule Disruption: MMAF inhibits microtubule dynamics, supporting studies of ADC-mediated cytotoxicity and cell-cycle arrest.
- Fc-Mediated Activity: The afucosylated antibody component supports research into antibody-dependent cellular cytotoxicity and phagocytosis.
Applications
- Multiple Myeloma Research: Supports studies of BCMA-targeted ADC mechanisms in multiple myeloma cell models.
- BCMA-Positive Cancer Research: Useful for investigating BCMA expression, targeting, and cytotoxic responses in relevant cancer models.
- Plasma Cell Biology: Supports research involving BCMA signaling, plasma cell survival, and malignant plasma cell biology.
- ADC Research: Useful for studying antibody targeting, internalization, intracellular processing, and payload activity.
- Targeted Cancer Research: Supports investigation of antibody-mediated delivery of cytotoxic payloads to BCMA-expressing cells.
- Cell-Based Cancer Assays: Especially useful for evaluating BCMA-dependent binding, internalization, cytotoxicity, and cellular responses.
- Mechanism-of-Action Studies: Supports investigation of MMAF-mediated microtubule disruption and Fc-mediated immune effector functions.
- Comparative ADC Research: Especially useful for evaluating BCMA-targeting strategies, non-cleavable linkers, and auristatin payloads.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody and conjugate stability.
Belantamab Mafodotin combines BCMA-directed antibody targeting with the microtubule-disrupting MMAF payload and specifically supports multiple myeloma research, BCMA-targeted ADC studies, plasma cell biology, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
